Advanced in Hemolysis

Dr. Robert C. Brown

Hematology Oncology
5461 Meridian Mark Rd Ste 400, 
Atlanta, GA 
Accepting New Patients
Advanced in Hemolysis
5461 Meridian Mark Rd Ste 400, 
Atlanta, GA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Robert Brown is a Hematologist Oncology provider in Atlanta, Georgia. Dr. Brown is rated as an Advanced provider by MediFind in the treatment of Hemolysis. His top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, and Hemolytic Anemia. Dr. Brown is currently accepting new patients.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Licenses
Internal Medicine in GA
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

5461 Meridian Mark Rd Ste 400, Atlanta, GA 30342

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab Versus Placebo, With or Without Hydroxyurea/ Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients With Vaso-Occlusive Crises (STAND)
A Phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab Versus Placebo, With or Without Hydroxyurea/ Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients With Vaso-Occlusive Crises (STAND)
Enrollment Status: Active_not_recruiting
Publish Date: September 24, 2025
Intervention Type: Drug
Study Drug: Crizanlizumab
Study Phase: Phase 3
A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Treatment Effect of GBT440 in Pediatric Participants With Sickle Cell Disease
A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Treatment Effect of GBT440 in Pediatric Participants With Sickle Cell Disease
Enrollment Status: Terminated
Publish Date: August 15, 2025
Intervention Type: Drug
Study Drug: Voxelotor
Study Phase: Phase 2
A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea/Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive Crisis
A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea/Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive Crisis
Enrollment Status: Completed
Publish Date: July 20, 2025
Intervention Type: Drug
Study Drug: Crizanlizumab
Study Phase: Phase 2
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants With Sickle Cell Disease (HOPE Kids 2)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants With Sickle Cell Disease (HOPE Kids 2)
Enrollment Status: Terminated
Publish Date: June 13, 2025
Intervention Type: Drug
Study Drug: Voxelotor
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
Enrollment Status: Completed
Publish Date: April 23, 2025
Intervention Type: Drug
Study Drug: Inclacumab
Study Phase: Phase 3
A Prospective Phase II, Open-Label, Single-arm, Multicenter, Study to Assess Efficacy and Safety of SEG101 (Crizanlizumab), in Sickle Cell Disease Patients With Priapism (SPARTAN)
A Prospective Phase II, Open-Label, Single-arm, Multicenter, Study to Assess Efficacy and Safety of SEG101 (Crizanlizumab), in Sickle Cell Disease Patients With Priapism (SPARTAN)
Enrollment Status: Completed
Publish Date: April 13, 2025
Intervention Type: Drug
Study Drug: Crizanlizumab
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises
Enrollment Status: Terminated
Publish Date: December 11, 2024
Intervention Type: Drug
Study Drug: Inclacumab
Study Phase: Phase 3
A Phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (Crizanlizumab), With or Without Hydroxyurea/Hydroxycarbamide, in Sickle Cell Patients With Vaso-Occlusive Crisis
A Phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (Crizanlizumab), With or Without Hydroxyurea/Hydroxycarbamide, in Sickle Cell Patients With Vaso-Occlusive Crisis
Enrollment Status: Completed
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drug: Crizanlizumab
Study Phase: Phase 2
An Intrapatient Single Dose and Multiple Ascending Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of GBT021601, a Hemoglobin S Polymerization Inhibitor, in Participants With Sickle Cell Disease (SCD)
An Intrapatient Single Dose and Multiple Ascending Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of GBT021601, a Hemoglobin S Polymerization Inhibitor, in Participants With Sickle Cell Disease (SCD)
Enrollment Status: Completed
Publish Date: June 10, 2024
Intervention Type: Drug
Study Drug: GBT021601
Study Phase: Phase 1
A Phase 4, Multicenter, Open-label Study to Evaluate the Treatment Effect of Voxelotor on Physical Activity in Adolescents and Adults With Sickle Cell Disease
A Phase 4, Multicenter, Open-label Study to Evaluate the Treatment Effect of Voxelotor on Physical Activity in Adolescents and Adults With Sickle Cell Disease
Enrollment Status: Completed
Publish Date: November 21, 2023
Intervention Type: Drug
Study Drug: Voxelotor
Study Phase: Phase 4
An Open-Label, Expanded Access Protocol for Patients With Sickle Cell Disease Who Have No Alternative Treatment Options
An Open-Label, Expanded Access Protocol for Patients With Sickle Cell Disease Who Have No Alternative Treatment Options
Enrollment Status: No_longer_available
Publish Date: July 18, 2023
Intervention Type: Drug
Hydroxyurea Management in Kids: Intensive Versus Stable Dosage Strategies
Hydroxyurea Management in Kids: Intensive Versus Stable Dosage Strategies
Enrollment Status: Completed
Publish Date: June 25, 2021
Intervention Type: Drug
Study Phase: Phase 2
Patient Centered Comprehensive Medication Adherence Management System to Improve Effectiveness of Disease Modifying Therapy With Hydroxyurea in Patients With Sickle Cell Disease
Patient Centered Comprehensive Medication Adherence Management System to Improve Effectiveness of Disease Modifying Therapy With Hydroxyurea in Patients With Sickle Cell Disease
Enrollment Status: Completed
Publish Date: March 05, 2021
Intervention Type: Behavioral
Study Phase: Not Applicable
View 12 Less Clinical Trials

3 Total Publications

Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial.
Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial.
Journal: The Lancet. Haematology
Published: January 06, 2021
Similar Doctors
Experienced in Hemolysis
Dr. Justin J. Yoo
Hematology Oncology | Pediatrics | Pediatric Hematology Oncology
Experienced in Hemolysis
Dr. Justin J. Yoo
Hematology Oncology | Pediatrics | Pediatric Hematology Oncology

The Emory Clinic Inc

1365 Clifton Rd Ne, 
Atlanta, GA 
 (7.0 miles away)
404-778-7525
Experience:
10+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Justin Yoo is a Hematologist Oncology specialist and a Pediatrics provider in Atlanta, Georgia. Dr. Yoo has been practicing medicine for over 10 years and is rated as an Experienced provider by MediFind in the treatment of Hemolysis. His top areas of expertise are Hemolytic Anemia, Anemia, Sickle Cell Disease, and Hemolysis. Dr. Yoo is currently accepting new patients.

Morgan L. Mclemore
Experienced in Hemolysis
Dr. Morgan L. Mclemore
Hematology Oncology
Experienced in Hemolysis
Dr. Morgan L. Mclemore
Hematology Oncology

Emory Hemophilia Of Georgia

550 Peachtree Street Northeast, MedicalOfficeTower, 
Atlanta, GA 
 (7.7 miles away)
404-778-1900
Experience:
36+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Morgan Mclemore is a Hematologist Oncology provider in Atlanta, Georgia. Dr. Mclemore has been practicing medicine for over 36 years and is rated as a Distinguished provider by MediFind in the treatment of Hemolysis. His top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Fanconi Anemia, Bone Marrow Aspiration, and Splenectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Brown's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile